AAIC 2025 Abstract

Plasma p ‐tau ₂₁₇ as a suitable biomarker for monitoring cognitive changes in Alzheimer's disease

By Davina Biel, Anna Steward, Anna Dewenter, Nicolai Franzmeier

Study in peopleBiomarkers

Abstract

Background: With the approval of anti‐amyloid therapies in Alzheimer's disease (AD), surrogate biomarkers are urgently needed to monitor treatment effects that translate into clinical benefits.

The paper

Davina Biel, Anna Steward, Anna Dewenter, Nicolai Franzmeier

Institut für Schlaganfall- und Demenzforschung; Munich Cluster for Systems Neurology

AAIC 2025 Abstract, 7 Jan 2026, CC BY

Presented at AAIC 2025

doi.org/10.1002/alz70856_104771

medRxiv4 Oct 2026
Tool converts plasma pTau217 values across testing platforms
Research Square4 Oct 2026
Brain diffusivity modifies plasma pTau217 links to pathology
medRxiv5 Oct 2026
Blood eMTBR-tau linked to Alzheimer’s tangles at autopsy
Neurology4 Oct 2026
Plasma p-tau217 yields discordant Alzheimer results in 8.5% of adults

Plasma p ‐tau ₂₁₇ as a suitable biomarker for monitoring cognitive changes in Alzheimer's disease

Abstract

The paper

Related

Tool converts plasma pTau217 values across testing platforms

Brain diffusivity modifies plasma pTau217 links to pathology

Blood eMTBR-tau linked to Alzheimer’s tangles at autopsy

Plasma p-tau217 yields discordant Alzheimer results in 8.5% of adults